At Washington Interventional Psychiatry (WIP), we are proud to offer SPRAVATO™ (intranasal esketamine), an FDA-approved S-ketamine treatment for depression. Serving residents across all of Washington, D.C., Maryland, and Virginia (DMV areas), our SPRAVATO® Treatment Center provides an innovative solution for individuals struggling with treatment-resistant depression or those seeking alternatives to traditional antidepressant medications. Compared to IV ketamine, this treatment is administered nasally. Consultations with our psychiatrists are complimentary, ensuring personalized and accessible care for your mental health needs.
Our (S-Ketamine) SPRAVATO™ program might be the right fit for you if:
If you’re unsure whether SPRAVATO™ is the right fit, our free consultation is a great way to explore your options and develop a treatment plan tailored to your needs.
SPRAVATO™ contains esketamine, a medication derived from ketamine, which has shown significant promise in relieving symptoms of depression. Unlike traditional antidepressants that can take weeks to show results, (S-Ketamine) SPRAVATO™ acts rapidly, targeting NMDA receptors in the brain to improve mood and reduce depressive symptoms.
This FDA-approved treatment is specifically designed for people who haven’t responded to other therapies. All sessions take place at our SPRAVATO® Treatment Center in Washington, D.C., where you’ll be closely monitored for at least two hours to ensure your safety throughout the entire process.
The administration and monitoring fee for SPRAVATO™ is $300 per session.
We assist with insurance coordination and provide clear guidance regarding anticipated out-of-pocket costs before treatment begins. For out-of-network plans, we offer access to Reimbursify to streamline reimbursement submissions.
Patient safety is central to every aspect of care at WIP. Following each ketamine treatment, patients remain in the clinic for observation and recovery under medical supervision. Vital signs, including blood pressure, are closely monitored and managed as needed.
Discharge timing is individualized based on clinical recovery criteria. Because ketamine may temporarily impair coordination and judgment, patients are not permitted to drive after treatment. Transportation home must be arranged in advance. A family member, friend, or professional car service may be used.
If you are considering SPRAVATO™ (esketamine) treatment for depression, we offer a complimentary psychiatrist-led consultation to determine whether it is clinically appropriate for you.
Our team will review eligibility, insurance considerations, and treatment planning in a structured and transparent manner.
Our SPRAVATO® Treatment Center is located at 4325 49th Street NW, Suite 200, Washington, D.C. 20016.
Structured psychiatric care for patients seeking a more comprehensive approach.
